RE:RE:Valeant Sells iNova For $930mPappa is refining their core business to return to growth by 2018. More non-core assest sales to come. Valeant’s eye-surgery assets may be valued at about $2 billion in a sale
Valeant Pharmaceuticals International in talks to sell Bausch & Lomb eye surgery unit to Carl Zeiss, sources say The deal could be announced in a few weeks.